Phase 3 Study of the Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Renal Outcomes in Humans With Diabetic Kidney Disease
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- MCP-1:Creatinine Ratio in Urine
研究概览
简要总结
Diabetic kidney disease (DKD) is a devastating complication of diabetes, that in it's worst form, can lead to early cardiovascular death or kidney failure. A group of medicines used to treat diabetes, glucagon-like-peptide-1 analogues (GLP-1), may be able to protect people with diabetes from DKD by reducing inflammation in the kidney. This study aims to test this theory by studying the effect of GLP-1 on kidney function in people with diabetes.
To understand how GLP-1 can affect inflammation, the investigators will give a GLP-1 treatment (Liraglutide) to people with DKD and monitor the effect on inflammation and kidney function using blood and urine tests. The investigators will compare these results to patients with DKD who do not receive GLP-1 treatment.
If GLP-1 proves to be effective in reducing inflammation and improving kidney function, then it could be developed as a viable new treatment for people with DKD, and may significantly reduce the disease burden, or the risk of DKD, in people with diabetes. This would be a major advance in the treatment of DKD.
详细描述
A randomised controlled trial for patients with microalbuminuria and type 2 diabetes. Treatment is 0.6mg of liraglutide and is compared to standard care. Treatment duration is 6 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 30 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Type 2 diabetes with a HbA1c of 42-75mmol/mol (6-9%DCCT)
- •Male or female aged above 30 years
- •Have a negative pregnancy test at screening (women of child bearing potential only)
- •Body mass index (BMI) of 25kg/m2 or greater
- •On a renin-angiotensin system antagonist, at a stable dose, for at least 8 weeks before inclusion into the study
- •Established microalbuminuria
- •Estimated glomerular filtration rate (eGFR) 30ml/min/1.73m2 or above by Modification of Diet in Renal Disease (MDRD) formula
排除标准
- •Patients with any cognitive impediment that preclude the patient from giving free and informed consent
- •Patients on dipeptidyl peptidase 4 inhibitors or thiazolidinedione treatment
- •Patients with stage 4-5 renal disease, defined as an eGFR of 30ml/min/1.73m2 or less
- •Patients who have used a GLP-1 agent in the last 6 months
- •Female patients of child bearing potential who are pregnant, breastfeeding, or unwilling to practice an acceptable barrier and/or hormonal method of contraception or abstinence during participation in the study
- •Previous pancreatitis
- •Hypersensitivity to GLP-1 analogues
- •Proliferative diabetic retinopathy
- •Any other contraindications, as per the SmPC for liraglutide
- •Patients with any other clinical condition or prior therapy that, in the opinion of the investigator, would make the patient unsuitable for the study or unable to comply with the dosing requirements
- •Concurrent treatment with an investigational drug or participation in another clinical trial
- •Use of an investigational drug within 4 weeks or 5 half-lives, whichever is longer, preceding the first dose of investigational medicinal product
研究组 & 干预措施
Liraglutide
Liraglutide 0.6 mg daily
干预措施: Liraglutide (Drug)
结局指标
主要结局
MCP-1:Creatinine Ratio in Urine
时间窗: Up to 26 weeks
Spot urine sample for MCP-1 and creatinine
次要结局
- Urine Albumin:Creatinine Ratio(Up to 26 weeks)
- Urinary Albumin Excretion Rate(Up to 26 weeks)
- sCD163 in Serum(Up to 26 weeks)
- sCD163:Creatinine Ratio in Urine(Up to 26 weeks)
研究者
Karl Neff
Clinical Research Fellow
University College Dublin